TY - JOUR
T1 - Vitreous biomarkers in diabetic retinopathy: A systematic review and meta-analysis
AU - Mcauley, A.K.
AU - Sanfilippo, Paul
AU - Hewitt, Alex
AU - Liang, H.
AU - Lamoureux, E.L.
AU - Wang, J.
AU - Connell, P.P.
PY - 2014/5
Y1 - 2014/5
N2 - The aim of this study was to perform a systematic meta-analysis of biomarkers investigated with diabetic retinopathy (DR) in the vitreous, and to explore the molecular pathway interactions of these markers found to be consistently associated with DR. Relevant databases [PubMed and ISI web of science] were searched for all published articles investigating molecular biomarkers of the vitreous associated with DR. Based on set exclusion/inclusion criteria available data from studies with human vitreous samples were extracted and used for our meta-analysis. The interactions of significant biomarkers in DR were investigated via STRING and KEGG pathway analysis. Our meta-analysis of DR identifies eleven biomarkers as potential therapeutic candidates alternate to current anti-VEGF therapy. Four of these are deemed viable therapeutic targets for PDR; ET receptors (ET A and ET B), anti-PDGF-BB, blocking TGF-β using cell therapy and PEDF. The identification of supplementary or synergistic therapeutic candidates to anti VEGF in the treatment of DR may aid in the development of future treatment trials. © 2014 Elsevier Inc.
AB - The aim of this study was to perform a systematic meta-analysis of biomarkers investigated with diabetic retinopathy (DR) in the vitreous, and to explore the molecular pathway interactions of these markers found to be consistently associated with DR. Relevant databases [PubMed and ISI web of science] were searched for all published articles investigating molecular biomarkers of the vitreous associated with DR. Based on set exclusion/inclusion criteria available data from studies with human vitreous samples were extracted and used for our meta-analysis. The interactions of significant biomarkers in DR were investigated via STRING and KEGG pathway analysis. Our meta-analysis of DR identifies eleven biomarkers as potential therapeutic candidates alternate to current anti-VEGF therapy. Four of these are deemed viable therapeutic targets for PDR; ET receptors (ET A and ET B), anti-PDGF-BB, blocking TGF-β using cell therapy and PEDF. The identification of supplementary or synergistic therapeutic candidates to anti VEGF in the treatment of DR may aid in the development of future treatment trials. © 2014 Elsevier Inc.
U2 - 10.1016/j.jdiacomp.2013.09.010
DO - 10.1016/j.jdiacomp.2013.09.010
M3 - Review article
C2 - 24630762
SN - 1056-8727
VL - 28
SP - 419
EP - 425
JO - Journal of Diabetes and Its Complications
JF - Journal of Diabetes and Its Complications
IS - 3
ER -